APA

Dodero A., Guidetti A., Tucci A., Barretta F., Novo M., Devizzi L., Re A., Passi A., Pellegrinelli A., Pruneri G., Miceli R., Testi A., Pennisi M., Di Chio M. C., Matteucci P., Carniti C., Facchetti F., Rossi G. & Corradini P. (20190809). Dose-adjusted EPOCH plus rituximab improves the clinical outcome of young patients affected by double expressor diffuse large B-cell lymphoma. : Leukemia.

Chicago

Dodero A, Guidetti A, Tucci A, Barretta F, Novo M, Devizzi L, Re A, Passi A, Pellegrinelli A, Pruneri G, Miceli R, Testi A, Pennisi M, Di Chio M C, Matteucci P, Carniti C, Facchetti F, Rossi G and Corradini P. 20190809. Dose-adjusted EPOCH plus rituximab improves the clinical outcome of young patients affected by double expressor diffuse large B-cell lymphoma. : Leukemia.

Harvard

Dodero A., Guidetti A., Tucci A., Barretta F., Novo M., Devizzi L., Re A., Passi A., Pellegrinelli A., Pruneri G., Miceli R., Testi A., Pennisi M., Di Chio M. C., Matteucci P., Carniti C., Facchetti F., Rossi G. and Corradini P. (20190809). Dose-adjusted EPOCH plus rituximab improves the clinical outcome of young patients affected by double expressor diffuse large B-cell lymphoma. : Leukemia.

MLA

Dodero A, Guidetti A, Tucci A, Barretta F, Novo M, Devizzi L, Re A, Passi A, Pellegrinelli A, Pruneri G, Miceli R, Testi A, Pennisi M, Di Chio M C, Matteucci P, Carniti C, Facchetti F, Rossi G and Corradini P. Dose-adjusted EPOCH plus rituximab improves the clinical outcome of young patients affected by double expressor diffuse large B-cell lymphoma. : Leukemia. 20190809.